Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163565 | 0.93 | F10 (0.53) | F10F2 | |
| SCHEMBL10163552 | 0.92 | F10 (0.51) | F10F2ITGB3PRSS1PRSS2 | |
| SCHEMBL10162624 | 0.91 | F10 (0.55) | F10F2ITGB3PRSS1PRSS2 | |
| SCHEMBL10162818 | 0.87 | F10 (0.53) | F10LMNAMAOAPTGS1MAOB | |
| SCHEMBL10162810 | 0.84 | MAOB (0.48) | F10MAOAMAOBCALML3 | |
| SCHEMBL10162513 | 0.82 | F10 (0.52) | F10F2LMNAMAOAPTGS1 | |
| SCHEMBL10162609 | 0.82 | F10 (0.50) | F10LMNAMAOAPTGS1MAOB | |
| SCHEMBL10162425 | 0.82 | MAOA (0.51) | F10LMNAMAOAPTGS1MAOB | |
| SCHEMBL10163577 | 0.81 | F10 (0.53) | F10F2LMNAMAOAPTGS1 | |
| SCHEMBL7299919 | 0.81 | SIGMAR1 (0.47) | F10MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | F10 2700/4885F2 1022/4885ITGB3 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.